ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,347,395 | -36.3% | 196,700 | -3.6% | 0.03% | -30.4% |
| Q2 2023 | $2,116,237 | -44.9% | 204,073 | -57.0% | 0.05% | -41.8% |
| Q1 2023 | $3,838,244 | +1038.9% | 474,443 | +2374.4% | 0.08% | +618.2% |
| Q2 2021 | $337,000 | -36.3% | 19,174 | -8.6% | 0.01% | -45.0% |
| Q1 2021 | $529,000 | +58.9% | 20,981 | -59.2% | 0.02% | +66.7% |
| Q4 2020 | $333,000 | +2461.5% | 51,461 | +339.8% | 0.01% | +1100.0% |
| Q3 2019 | $13,000 | -97.6% | 11,700 | -43.5% | 0.00% | -98.9% |
| Q3 2017 | $535,000 | +52.9% | 20,711 | +60.3% | 0.09% | +21.9% |
| Q2 2017 | $350,000 | -62.8% | 12,920 | -59.0% | 0.07% | -58.3% |
| Q1 2017 | $940,000 | +256.1% | 31,545 | +224.8% | 0.18% | +191.7% |
| Q4 2016 | $264,000 | – | 9,713 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |